heiDATA

Metrics

207,636 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Publication Year: 2023

41 to 50 of 2,585 Results

Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Nov 25, 2023 - Sektion Endokrinologie - Universitätsmedizin Mannheim Vardarli, Irfan; Tan, Susanne; Brandenburg, Tim; Weidemann, Frank; Görges, Rainer; Herrmann, Ken; Führer, Dagmar, 2023, "Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]", https://doi.org/10.11588/data/AWIFGR, heiDATA, V1, UNF:6:qBMlvagCg7J7FP6FCbo+5Q== [fileUNF] Supplemental Materials Abstract Context Few meta-analyses regarding the incidence of endocrine immune related adverse effects (eirAEs) have been published and many trials were published thereafter. Objective To assess the risk and incidence of eirAEs of any grade and grade 3-5 by...
Vardarli_Supplemental Figure legends.docx Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] MS Word - 13.8 KB - MD5: ba86a43da420eaea333e3062bed27e31 Supplemental Figure legends
Vardarli_Supplemental Table legends.docx Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] MS Word - 13.3 KB - MD5: 7c350502f033008bfdfc0f43b17b6199 Supplemental Table legends
Vardarli_Suppl Fig 10.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.9 KB - MD5: c2336ab9d2a1150d9356954216d18806 Suppl. Fig. 10. Forest plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 11.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 81.0 KB - MD5: 6b06e3d9ad6b0454073d242b7d5e02f5 Suppl. Fig. 11. Forest plot for cumulative meta-analysis for trials investigating hypophysitis/hypopituitarism any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 12.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.8 KB - MD5: ee9296c71046c73cc5fe678fec8a7720 Suppl. Fig. 12. Forest plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 13.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 124.0 KB - MD5: aa6c4221952b4830ebf248f5169fc5ef Suppl. Fig. 13. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 14.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.9 KB - MD5: 62d291378b75e8e2a2f5a787bcfce5a4 Suppl. Fig. 14. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 15.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.7 KB - MD5: e92bdfe54f4b36c5ebfe57df75bd5ca9 Suppl. Fig. 15. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 16.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.0 KB - MD5: 7f9fed59c4ed1df3ea37f159e262e680 Suppl. Fig. 16. Forest plot for leave-one out meta-analysis for trials investigating insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Nov 25, 2023 - Sektion Endokrinologie - Universitätsmedizin Mannheim

Vardarli, Irfan; Tan, Susanne; Brandenburg, Tim; Weidemann, Frank; Görges, Rainer; Herrmann, Ken; Führer, Dagmar, 2023, "Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]", https://doi.org/10.11588/data/AWIFGR, heiDATA, V1, UNF:6:qBMlvagCg7J7FP6FCbo+5Q== [fileUNF]

Supplemental Materials Abstract Context Few meta-analyses regarding the incidence of endocrine immune related adverse effects (eirAEs) have been published and many trials were published thereafter. Objective To assess the risk and incidence of eirAEs of any grade and grade 3-5 by...

Vardarli_Supplemental Figure legends.docx

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

MS Word - 13.8 KB -

Supplemental Figure legends

Vardarli_Supplemental Table legends.docx

MS Word - 13.3 KB -

Supplemental Table legends

Vardarli_Suppl Fig 10.pdf

Adobe PDF - 123.9 KB -

Suppl. Fig. 10. Forest plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 11.pdf

Adobe PDF - 81.0 KB -

Suppl. Fig. 11. Forest plot for cumulative meta-analysis for trials investigating hypophysitis/hypopituitarism any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 12.pdf

Adobe PDF - 123.8 KB -

Suppl. Fig. 12. Forest plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 13.pdf

Adobe PDF - 124.0 KB -

Suppl. Fig. 13. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 14.pdf

Adobe PDF - 80.9 KB -

Suppl. Fig. 14. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 15.pdf

Adobe PDF - 123.7 KB -

Suppl. Fig. 15. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 16.pdf

Adobe PDF - 80.0 KB -

Suppl. Fig. 16. Forest plot for leave-one out meta-analysis for trials investigating insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications